Please try another search
For the fiscal year ended 31 December 2021, Singapore O&G Ltd revenues increased 6% to SP$42.4M. Net income decreased 12% to SP$8.4M. Revenues reflect Dermatology segment increase of 31% to SP$8.8M, Paediatrics segment increase of 20% to SP$5.9M. Net income was offset by Employee remuneration expense increase of 10% to SP$21.3M (expense), JSS grant decrease of 78% to SP$195K (income). Dividend per share remained flat at SP$0.02.
Period Ending: | Dec 31, 2021 | Jun 30, 2021 | Dec 31, 2020 | Jun 30, 2020 |
---|---|---|---|---|
Total Revenue | 21.34 | 21.06 | 22.02 | 17.86 |
Gross Profit | 17.62 | 17.41 | 18.35 | 14.84 |
Operating Income | 4.58 | 5.48 | 6.25 | 4.53 |
Net Income | 3.85 | 4.52 | 5.7 | 3.79 |
Period Ending: | Dec 31, 2021 | Jun 30, 2021 | Dec 31, 2020 | Jun 30, 2020 |
---|---|---|---|---|
Total Assets | 57.79 | 53.76 | 57.86 | 51.48 |
Total Liabilities | 15.06 | 11.83 | 14.82 | 11.57 |
Total Equity | 42.72 | 41.93 | 43.04 | 39.91 |
Period Ending: | Dec 31, 2021 | Jun 30, 2021 | Dec 31, 2020 | Jun 30, 2020 |
---|---|---|---|---|
Period Length: | 12 Months | 6 Months | 12 Months | 6 Months |
Cash From Operating Activities | 11.88 | 3.6 | 14.39 | 4.97 |
Cash From Investing Activities | -1.12 | -1.05 | -0.42 | -0.29 |
Cash From Financing Activities | -10.51 | -6.55 | -4.43 | -1.02 |
Net Change in Cash | 0.25 | -4 | 9.53 | 3.65 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review